Viking Therapeutics Company

Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.
Viking Therapeutics is a clinical-stage biotherapeutics company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Viking’s research and development activities leverage the Company’s expertise in metabolism to develop innovative therapeutics that improve patients’ lives. The Company’s lead clinical program is VK0612, a first-in-class, orally available drug candidate type 2 diabetes. The Company’s second clinical program is VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, for the treatment of cancer cachexia. Viking is also developing three novel preclinical programs targeted at metabolic diseases and anemia.
Technology: Preventive Medicine
Industry: Precision Medicine
Headquarters: San Diego
Founded Date: 2012
Employees Number: 1-10
Funding Status: IPO

Visit Website
info@vikingtherapeutics.com
https://www.twitter.com/viking_vktx
Register and Claim Ownership